MedTrace Logo

Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter

NCT01270152 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2011-01-05

No results posted yet for this study

Summary

The hypothesis of the study is to evaluate whether ascorbic acid is able to clear totally implanted central venous catheter

Conditions

  • Occluded Totally Implanted Central Venous Catheter

Interventions

DRUG

Ascorbic Acid

comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Christiane I Vasques, Doc · University of São Paulo, College of Nursing at Ribeirão Preto

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-12-31
Completion
2010-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270152 on ClinicalTrials.gov